Thomson Reuters Spotlights the Impact of Personalized Medicine on Pharmaceutical R&D

Posted on by

New report details the potential advantages and challenges for the pharma industry as it implements strategies for personalized medicine

PHILADELPHIA, PA, December 13, 2012 - The IP & Science business of Thomson Reuters,the world`s leading source of intelligent information for businesses and professionals, today announced the publication of a new report that provides a comprehensive view of the potential effects of personalized medicine on drug research and development. Spotlight on Personalized Medicine, a Pharma Matters report based on insights and information from Thomson Reuters Cortellis for Competitive Intelligence and a selection of data from CMR International, details the current challenges posed by the paradigm of stratified medicine as well as its clinical, economic and societal value.

"An array of scientific and market factors have prompted the pharma industry to question the sustainability of the current R&D model, which targets large populations with chronic unmet medical needs," said Jon-Brett Harris, executive vice president at Thomson Reuters. "Despite the commercial success of these products, the one-size-fits-all focus has resulted in spiraling R&D costs, longer development timelines and narrow product portfolios. New options, specifically personalized medicine, appear to be an attractive and more sustainable solution. This new report offers a detailed look into the possible advantages and disadvantages of this potentially game-changing approach."

The report shows that a stratified paradigm could result in more efficient ways of conducting drug development, as well as address increased public awareness related to post-marketing withdrawals of popular drugs and debates concerning drug pricing and reimbursement. Further, the ability to better assess biological factors related to disease and therapy at the genetic level lends itself to the development of safer, more effective treatments for specific patient subgroups.

The slow pace of the industry to adopt a more stratified approach has been reinvigorated with high-profile drug launches and successes; however, numerous challenges still exist that could affect a large-scale integration of the personalized medicine paradigm into biopharmaceutical R&D. Analysis from Thomson Reuters Cortellis for Competitive Intelligence suggests a gap in connecting the dots between genetic variation, disease association, patient segments with those variations, clinical trial design and patient recruitment in the clinic.

Thomson Reuters Cortellis, the premier life sciences platform, is the most powerful tool of its kind for biopharmaceutical competitive intelligence, drug pipeline, and drug research and development information. CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. To learn more about Cortellis and CMR International, visit: http://ip-science.thomsonreuters.com/.

Click here to view Spotlight on Personalized Medicine.

Thomson Reuters Thomson Reuters is the world`s leading source of intelligent information for businesses and professionals.We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world`s most trusted news organization.With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to http://www.thomsonreuters.com.

CONTACT Jen Breen Thomson Reuters Jennifer.breen@thomsonreuters.com +1 215 823 1791

Abbey Anderson Thomson Reuters Abbey.anderson@thomsonreuters.com + 1 215 823 1894

Read more here:

Thomson Reuters Spotlights the Impact of Personalized Medicine on Pharmaceutical R&D

Research and Markets: Molecular Medicine. Edition No. 4

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xhrqtk/molecular) has announced the addition of Elsevier Science and Technology's new book "Molecular Medicine. Edition No. 4" to their offering.

Molecular Medicine is the application of genetic or DNA-based knowledge to the modern practice of medicine. Molecular Medicine, 4e, provides contemporary insights into how the genetic revolution is influencing medical thinking and practice. The new edition includes recent changes in personalized medicine, new growth in omics and direct-to-consumer DNA testing, while focusing on advances in the Human Genomeproject and implications of the advances in clinical medicine. Graduate students, researchers, clinicians and allied health professionals will appreciate the background history and clinical application of up-to-date molecular advances.

Key Features

- Extensively revised to incorporate the results of the Human Genome Project, it provides the latest developmentsin molecular medicine

- The only book in Molecular Medicine to reach its fourth edition

- Identifies current practice as well as future developments

- Presents extensive tables, well presented figures and resources for further understanding

Topics Covered:

Dedication and Acknowledgements

Read more here:

Research and Markets: Molecular Medicine. Edition No. 4

The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee

Posted on by

WASHINGTON, Dec. 13, 2012 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced the formation of a Tissue Engineering and Biomaterials Committee (TEBC). The TEBC has been established to assemble the companies, academic institutions, and organizations within the Alliance for Regenerative Medicine that develop and commercialize tissue engineered and biomaterial based technologies. The primary purpose of the TEBC is to develop a better understanding of the key barriers to translation and scale up of regenerative medicine technologies including challenges in efficient product design, pilot and scale up manufacturing, regulation, and reimbursement. In addition the TEBC will focus on building public awareness of this new field of medicine and an appreciation for its potential to transform healthcare.

Members of the TEBC will include private and public sector representatives involved in the field of tissue engineering. Tissue engineered technologies are being developed as clinical therapeutics to improve biological functions primarily through the repair, restoration, or total replacement of tissue or organ and are also being developed and commercialized as 3D tissue models and micro-organs to provide better research tools for drug discovery and clinical diagnostics. The TEBC group will include experts from interdisciplinary technologies that utilize cells, biomaterials, growth factors, small molecules, scaffolds, and other therapeutic agents to affect tissue growth or regeneration. The Committee will be led by Sarah Haecker PhD, a member of ARM's senior staff. Sarah has more than 20 years of experience in the industry and for the last seven years has specialized in working with companies in the tissue engineering sector.

"We will work to identify and capitalize on opportunities that accelerate product development and commercialization of these innovative regenerative medicine technologies," said Sarah Haecker. "The primary purpose of the TEBC is to determine the unique requirements which will, ultimately, advance and broaden the use of clinical tissue engineered paradigms world-wide."

"To successfully design, develop, and commercialize complex tissue engineered products, it is critical to bring together the leading experts in a multitude of disciplines and technology areas," said Robert Palay, co-chair of the TEBC and Chief Executive Officer of Cellular Dynamics International, Inc. "I am excited to be working with this group which is strategically designed and uniquely qualified to best move the wide range of tissue engineered products forward."

"Tissue engineering has tremendous potential to treat patients suffering from the loss of tissues and organs," said Jennifer H. Elisseeff, co-chair of the TEBC and Professor, Wilmer Eye Institute and Department of Biomedical Engineering, Johns Hopkins University. "We have the ability to establish the critical early and robust communication between the product designers and clinicians to support the successful path through commercialization of these complex products."

"Through the work of the TEBC, we hope to bring tissue engineered therapeutics to patients worldwide more quickly," said Michael Abecassis, MD, co-chair of the TEBC and Founding Director, Northwestern University Comprehensive Transplant Center. "We intend to develop a better understanding amongst key stakeholders as to the requirements to develop a more predictable regulatory pathway and a rational reimbursement framework for tissue engineered and biomaterial based products."

Members of the Tissue Engineering and Biomaterials Committee:

Cellular Dynamics, Circle Biologics, Harvard Bioscience, Histogenics, InVivo Therapeutics, ISTO, JDRF, Johns Hopkins University, McGowan Institute for Regenerative Medicine, MiMedx, Nanofiber Solutions, Northwestern University Comprehensive Transplant Center, Northwestern University's Feinberg School of Medicine, New York Stem Cell Institute, Organogenesis, Organovo, Pfizer, Sanofi Genzyme, Shire Regenerative Medicine, Tengion, Texas Heart Institute, Wake Forest Institute for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Originally posted here:

The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee

Cataract Surgery (Part 2 of 4) | Dr. David Richardson – Video

Posted on by


Cataract Surgery (Part 2 of 4) | Dr. David Richardson
Recommended Cataract Surgery Book For Cataract Patients: "So You #39;ve Got A Cataract?" | What You Need to Know About Cataract Surgery: A Patient #39;s Guide to Modern Eye Surgery, Advanced Intraocular Lenses Choosing Your Surgeon. http://www.cataract-book.com David D. Richardson, MD (aka "The Cataract Coach") describes modern cataract surgery in real time. Dr. David Richardson, MD, is a graduate of both the University of Southern California and Harvard Medical School. He has received multiple national awards and scholarships, including the Phi Beta Kappa Scholarship and the Harvard National Scholarship. After medical school he completed his residency in ophthalmology at the Doheny Eye Institute, one of the top eye surgery programs in the United States. Today, he is in private practice with offices in Pasadena and San Gabriel, California. An accomplished board-certified surgeon, Dr. Richardson has performed thousands of advanced cataract procedures with excellent results. In a survey of physicians he was voted a Pasadena Magazine "Top Doc" in 2008, 2009, 2010, 2011, and 2012 as well as a Los Angeles Magazine "Super Doctor" in 2010, 2011, and 2012. He has also been the recipient of the Patient #39;s Choice award as well as the Most Compassionate Doctor award. He can be reached through his Web site at http or by calling his office at (626) 289-7856.From:David RichardsonViews:2 0ratingsTime:03:55More inScience Technology

Continue reading here:

Cataract Surgery (Part 2 of 4) | Dr. David Richardson - Video

Cataract Surgery (Part 3 of 4) | Dr. David Richardson – Video

Posted on by


Cataract Surgery (Part 3 of 4) | Dr. David Richardson
Recommended Cataract Surgery Book For Cataract Patients: "So You #39;ve Got A Cataract?" | What You Need to Know About Cataract Surgery: A Patient #39;s Guide to Modern Eye Surgery, Advanced Intraocular Lenses Choosing Your Surgeon. http://www.cataract-book.com David D. Richardson, MD (aka "The Cataract Coach") describes modern cataract surgery in real time. Dr. David Richardson, MD, is a graduate of both the University of Southern California and Harvard Medical School. He has received multiple national awards and scholarships, including the Phi Beta Kappa Scholarship and the Harvard National Scholarship. After medical school he completed his residency in ophthalmology at the Doheny Eye Institute, one of the top eye surgery programs in the United States. Today, he is in private practice with offices in Pasadena and San Gabriel, California. An accomplished board-certified surgeon, Dr. Richardson has performed thousands of advanced cataract procedures with excellent results. In a survey of physicians he was voted a Pasadena Magazine "Top Doc" in 2008, 2009, 2010, 2011, and 2012 as well as a Los Angeles Magazine "Super Doctor" in 2010, 2011, and 2012. He has also been the recipient of the Patient #39;s Choice award as well as the Most Compassionate Doctor award. He can be reached through his Web site at http or by calling his office at (626) 289-7856.From:David RichardsonViews:2 0ratingsTime:03:20More inScience Technology

Continue reading here:

Cataract Surgery (Part 3 of 4) | Dr. David Richardson - Video

A growing role for beta-catenin in colon cancer – Video

Posted on by


A growing role for beta-catenin in colon cancer
The Wnt/beta-catenin pathway is mutated in virtually all cases of colon cancer, but scientists have not been able to target it with drugs. In this video, Broad Institute senior associate member William Hahn, who is also an associate professor at the Dana--Farber Cancer Institute and Harvard Medical School, describes new work that uses RNAi and dozens of cell lines from the Cancer Cell Line Encyclopedia to reveal previously unknown members of that pathway, opening the door to potential new treatment strategies. Read more about this work in a Broad news story (www.broadinstitute.orgFrom:broadinstituteViews:2 0ratingsTime:03:22More inScience Technology

View original post here:

A growing role for beta-catenin in colon cancer - Video

Geisel School of Medicine at Dartmouth – Improving Lives of Communities Through Excellence – Video

Posted on by


Geisel School of Medicine at Dartmouth - Improving Lives of Communities Through Excellence
The Geisel School of Medicine at Dartmouth is the fourth oldest medical school in the country and has a rich tradition. Its investigators at COBRE...the Center for Biomedical Research Excellence...are looking at new means of understanding and harnessing the immune system to prevent, diagnose and treat human diseases. There are exciting things going on at the school set in a quintessential New England town. geiselmed.dartmouth.eduFrom:WebsEdgeHealthViews:0 0ratingsTime:06:40More inScience Technology

Read this article:

Geisel School of Medicine at Dartmouth - Improving Lives of Communities Through Excellence - Video

2012-12-07 A day of Art in Chicago. Glass art of Jeffery Sarmiento. – Video

Posted on by


2012-12-07 A day of Art in Chicago. Glass art of Jeffery Sarmiento.
We spent a day downtown to see Jeffery #39;s Glass Art.What a an artist in full blossom. We saw him refused go into medicine even when he was admitted to medical school and pursued his dream. It was disappointed for Rudy and Aida in those day. Now he is a accomplished internal known artist. They are so proud of him and we do too. Go! Jeff.From:steve linViews:0 0ratingsTime:10:50More inTravel Events

The rest is here:

2012-12-07 A day of Art in Chicago. Glass art of Jeffery Sarmiento. - Video

Dangers of Polyneuropathy | In Good Shape — Interview – Video

Posted on by


Dangers of Polyneuropathy | In Good Shape -- Interview
Dr. Katrin Hahn talks about dangers of Polyneuropathy. She is a physician at the clinic for neurology at Berlin #39;s Charit Medical School and treats patients facing a host of different neurological disorders. For more go to: http://www.dw.deFrom:deutschewelleenglishViews:0 0ratingsTime:04:45More inHowto Style

Read the original:

Dangers of Polyneuropathy | In Good Shape -- Interview - Video

Top Medical Universities from China, Romania, Ukraine, Russia, – Video

Posted on by


Top Medical Universities from China, Romania, Ukraine, Russia,
WELCOME TO OVERSEAS CAREER CO.This co. is Direct bds,mds,pg dental in medical universities or medical colleges.no Exam for mbbs or pg entrance in university of ukraine,china,russia ,romania university. medical colleges abroad,how to study medicine,study entrance,medical course,medical studies,medical study,study medical,mbbs admissions,pg medical entrance,medical admissions,medical entrance,medical university,medical colleges,mds medical schools,mbbs,ukraine,medical universities,medical school admission,foreign universities for mbbs etc.contact no.09212623658,Phone 011-26781098, 26783956 Mail ID:-career@overseascareer.net/More detail login:-www.overseascareer.netFrom:OverseasconsultancyViews:0 0ratingsTime:01:10More inEducation

Visit link:

Top Medical Universities from China, Romania, Ukraine, Russia, - Video

Medical School Admission ,Mbbs Admissions – Video

Posted on by


Medical School Admission ,Mbbs Admissions
WELCOME TO OVERSEAS CAREER CO.This co. is Direct bds,mds,pg dental in medical universities or medical colleges.no Exam for mbbs or pg entrance in university of ukraine,china,russia ,romania university. medical colleges abroad,how to study medicine,study entrance,medical course,medical studies,medical study,study medical,mbbs admissions,medical universities,medical school admission,foreign universities for mbbs etc.contact no.09212623658,Phone 011-26781098, 26783956 Mail ID:-info@overseascareer.net/ career@overseascareer.net More detail login:-www.overseascareer.netFrom:OverseasconsultancyViews:0 0ratingsTime:01:39More inEducation

Read the rest here:

Medical School Admission ,Mbbs Admissions - Video

Meet Dr. David I. Hoffman – Video

Posted on by


Meet Dr. David I. Hoffman
Dr. David I. Hoffman, is Board Certified in Obstetrics and Gynecology and subspecialty Board Certified in Reproductive Endocrinology and Infertility. He has over 25 years of experience in the diagnosis and treatment of infertility, currently serves as a Voluntary Clinical Assistant Professor, Department of Obstetrics and Gynecology, Florida International University as well as a Voluntary Associate Professor, Department of Obstetrics and Gynecology, University of Miami, Miller School of Medicine. He is affiliated with Northwest Medical Center and the Memorial Health System. Dr. Hoffman joined the Northwest Center for Infertility and Reproductive Endocrinology in South Florida in 1989, and he sees patients at IVF Florida Reproductive Associates. Prior to this, Dr. Hoffman served on the faculty at the University of Southern California in Los Angeles, and was Assistant Professor in the Department of Obstetrics and Gynecology at Northwestern University in Chicago, Director of the IVF Program at Northwestern Memorial Hospital, and Section Head of the Division of Reproductive Endocrinology and Infertility at Northwestern University Medical School. Dr. Hoffman is a native of Pennsylvania, and graduated from Trinity College in Hartford, Connecticut, before attending medical school at Temple University. He completed his residency in Obstetrics and Gynecology and his fellowship in Reproductive Endocrinology at the University of Southern California. Dr. Hoffman has received numerous ...From:CureusIncViews:0 0ratingsTime:02:23More inScience Technology

Read the original:

Meet Dr. David I. Hoffman - Video

Peter Blume-Jensen from Metamark Genetics – Video

Posted on by


Peter Blume-Jensen from Metamark Genetics
Peter Blume-Jensen, Chief Scientific Officer of Metamark Genetics, sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss their novel platform Prognosis Determinant. "Through its proprietary Prognosis Determinant trade; Discovery Platform, Metamark has identified and validated functionally active genetic determinants of metastasis that are critical to the progression of a broad spectrum of tumor types." - http://www.metamarkgenetics.com The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:44 0ratingsTime:02:57More inScience Technology

Read the original post:

Peter Blume-Jensen from Metamark Genetics - Video

Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants – Video

Posted on by


Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants
Peter Blume-Jensen, Chief Scientific Officer of Metamark Genetics, sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss their novel platform Prognosis Determinant. "Through its proprietary Prognosis Determinant trade; Discovery Platform, Metamark has identified and validated functionally active genetic determinants of metastasis that are critical to the progression of a broad spectrum of tumor types." - http://www.metamarkgenetics.com The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:10 0ratingsTime:02:41More inScience Technology

See original here:

Peter Blume-Jensen of Metamark Genetics on Prognosis Determinants - Video

Joslin Diabetes Center and Humedica Launch Strategic Collaboration to Improve Quality and Efficiency of Care and …

Posted on by

BOSTON--(BUSINESS WIRE)--

Joslin Diabetes Center, an affiliate of Harvard Medical School, has joined forces with Humedica to redefine traditional models of continuing medical education (CME) by leveraging Humedicas de-identified clinical data assets and offering providers an opportunity to participate in education or research activities designed to improve care based on identified gaps.

The collaboration is kicking off with a series of innovative projects, each starting with a baseline analysis of retrospective real-world practice patterns of patients with type 2 diabetes. Each analysis includes both process measures and patient outcomes data. Initial topics include:

I. Comparison of data methods for assessing physicians practice patterns

II. Improving clinician proficiency in insulin initiation and management

III. Examining barriers to optimal care of patients with post-prandial glycemia

John Brooks, President and Chief Executive Officer of Joslin says, "Big data provides a new frontier to drive health care quality improvements, and Humedica is well positioned to support Joslin in our ongoing efforts to positively impact diabetes care through data analytics and clinical support driven initiatives.

Michael Weintraub, Humedicas President and CEO, adds, Working with Joslin is a natural fit for us. Supporting research that examines and improves the way healthcare is delivered is an extension of the value we create for our providers today - transforming clinical data into actionable insights and meaningful results.

Humedica will be providing Joslins researchers access to a de-identified clinically robust, population health data set, and coordinating with their partner, the American Medical Group Association (AMGA) to engage providers to participate in performance focused CME or other research initiatives. Current projects are supported via independent educational grants from Sanofi, Pfizer, GlaxoSmithKline and Lilly.

This is the new direction for continuous quality improvement, adds Julie Brown, CCMEP, director of professional education at Joslin. Through the combination of Humedicas clinical data and provider network, and Joslins performance focused CME program, we are able for the first time to efficiently leverage actual clinical performance and outcomes so we can better understand physicians unmet needs in diabetes and cardiometabolic health. Only then can we prospectively address these gaps through targeted interventions. This data-education combination will position continuing medical education where it belongs - at the center of medical practice where it can be used as a tool to enhance quality and value.

Original post:

Joslin Diabetes Center and Humedica Launch Strategic Collaboration to Improve Quality and Efficiency of Care and ...

Caribbean Medical School UMHS St. Kitts Approved for Veteran's Benefits

Posted on by

The University of Medicine and Health Sciences (UMHS), a state-of-the-art medical school known for its individual student attention, has been approved by the Department of Veterans Affairs (VA), enabling eligible veterans, servicepersons, and certain dependents of veterans to receive VA educational benefits.

St. Kitts, West Indies (PRWEB) December 13, 2012

Eligible persons may receive benefits under one of several types of GI Bill:

UMHS is also announcing the formation of the Robert Ross Veterans Scholarship. This is a needs based scholarship available to veterans and servicemen during the Basic Science Program. Students may be eligible for up to $1,000 per semester of additional funding.

"This is great news for any prospective or current students who come to us from military backgrounds." ~Sean Powers, Director of Admissions, UMHS

Caribbean medical schools are a popular alternative for American and Canadian students who are unable to gain admission to overwhelmingly competitive domestic schools. Known for its outstanding US and Canadian faculty, small classes, and impressive facilities, UMHS has quickly become one of the best options for medical education in the Caribbean. Offshore medical schools like UMHS are especially important for non-traditional students, such as veterans, who might not fit the standard student profile of a domestic medical school. Caribbean medical schools offer non-traditional students a second chance, giving them a high quality education, resulting in the opportunity to earn a residency in the United States and Canada.

New VA applicants are encouraged to visit the VA's web site http://www.gibill.va.gov and fill out the online applications that are available. UMHS will be posting more details on its website about both the scholarship program and VA benefits. Students interested in either program should contact the office of financial aid and registrar for further details.

About UMHS:

The University of Medicine and Health Sciences (UMHS) is a Caribbean medical school, founded in 2007, offering a Doctor of Medicine degree program. Students begin their basic science studies in St. Kitts, West Indies, and complete their clinical training in teaching hospitals throughout the United States. UMHS prides itself on its state-of-the-art campus, small class sizes, high student retention, and near perfect USMLE passing rates.

For more information about UMHS, visit our website or check out our Caribbean medical school blog: the UMHS Pulse. Prospective students, advisors and faculty can reach us as 866-686-0380.

Read the original post:

Caribbean Medical School UMHS St. Kitts Approved for Veteran's Benefits